AstraZeneca's Product Gefurulimab Once-weekly self-administered subcutaneous C5 inhibitor showed statistically significant and clinically meaningful reduction in disease severity at week 26. Positive high-level results from a global, randomised, double-blind, placebo-controlled Phase III trial in adults with anti-acetylcholine receptor (AChR) antibody-positive (Ab+) generalised myasthenia gravis showed that gefurulimab met its primary and all secondary endpoints. Data demonstrated a statistically significant and clinically meaningful improvement from baseline …
AstraZeneca in the NEWS Cornerstone of investment is a proposed new multi-billion dollar drug substance manufacturing center focused on chronic diseases in the Commonwealth of Virginia, the Company’s largest single Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% investment in a facility to date AstraZeneca (AZN) announces $50 billions of investment in the . . . This content is …
Axsome Therapeutics Axsome Therapeutics (AXSM) is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. The Company delivers scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Axsome industry-leading neuroscience portfolio includes FDA-approved . . . This content is for …
Friday, August 18, 2025 Solid Earning, revenue growth, President Trump signing crypto bills, and Crispr Therapeutics stocks finally surge with the stocks following are happening today in spite of extreme bad weather in some states, problems of important people from Epstein with many people visited him as friends not for anything else. While we enjoyed the surge of Crispr Therapeutics, we decided to remind the …
Alnylam Pharmaceutical's News Today is Great Before we get to the press release from Alnylam Pharmaceuticals we remind that tomorrow, Tuesday, June 10, 2025, Akero Therapeutics’ management will present at Goldman Sachs 46th Annual Global Healthcare Conference at 2:40 pm Et. The presentation will be available through the investor relations section of the company’s website at www.akerotx.com. An archived replay will be available for those …
Vera Therapeutics As expected, Vera Therapeutics (VERA) product Ataticept achieved proteinuria reduction in ORIGIN Phase 3 trials in adults with IgA nephropathy. This is indeed great news! The trial met the primary endpoint at week 36. Ataticept has achieved 46%reduction from baseline and 42%reduction compared to placebo on wek 36. Vera is not sharing cGFR at this time . . . This content is for …
Alnylam Pharmaceuticals Synopsis Today, May 1, 2025 - Alnylam Pharmaceuticals (ALNY), the leading RNAi therapeutics company reported its consolidated financial results for the first quarter ended March 31, 2025 and reviewed recent business highlights. From Alnylam Pharmaceuticals Yvonne Greenstreet, M.D., Chief Executive Officer of Alnylam Pharmaceuticals, said, “2025 is off to a remarkable start, having ended the first quarter with U.S . . . This …
BridgeBio Pharma Today, March 24, 2025, BridgeBio Pharma, Inc. (BBIO) announced that cardiovascular outcomes data in patients with variant and wild-type ATTR-CM from the ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be shared in a flatboard poster presentation at the American College . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Alnylam Pharmaceuticals in the NEWS March 20, 2025, Alnylam Pharmaceuticals (ALNY) - the leading RNAi therapeutics company, today announced that the U.S. FDA has approved the supplemental New Drug Application (sNDA) for its RNAi therapeutic, AMVUTTRA® (vutrisiran), for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to . . . This content is for paid subscribers. Please click here to subscribe or …
Pyxis Oncology in the NEWS Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update On March 18, 2025, Pyxis Oncology (PYXS) - a clinical-stage firm developing next-generation therapeutics for difficult-to-treat cancers, reported financial results for the year and quarter ending December 31, 2024, and provided a business update. From Pyxis Oncology Lara . . . This content is for paid …
With a bad market and a lot of talk about recession and shutting down the Government, with most stocks tanking, in the middle of this chaos some biotech companies, that we selected for investment, have beaten the bad news and moved up, instead of sinking to the bottom of an uneasy ocean. These stocks closed today at: Stock Symbol Price Change
AstraZeneca AstraZeneca (AZN) has positive high-level results from the MATTERHORN Phase III trial, which showed perioperative treatment with AstraZeneca’s Imfinzi (durvalumab) in combination with standard-of-care FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival (
Jazz Pharmaceuticals to Acquire Chimerix Today, March 5, 2025, Jazz Pharmaceuticals (JAZZ) and Chimerix (CMRX) announced the companies have entered into a definitive agreement for Jazz . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
– Showcases multiple potentially transformative near- and mid-stage therapies in ATTR amyloidosis, cardiovascular disease, and Neuroscience, each representing a blockbuster opportunity – – Announces TRITON Phase 3 program for next-generation TTR silencer nucresiran in ATTR-CM and hATTR-PN, targeting durable franchise leadership – – Provides details about Phase 3 cardiovascular outcomes trial for zilebesiran, poised to transform the treatment of hypertension in patients with high CV risk – …
Sanofi A scheduled review of the E.mbrace phase 3 study (clinical trial identifier: NCT04899336) conducted by an independent data monitoring committee (IDMC) determined that Sanofi (SNY) and Johnson & Johnson’s (
Eledon Pharmaceuticals The patient was treated in the procedure, conducted at Mass General Transplant Center and in collaboration with partner eGenesis, and was recently released from the hospital. Today, February 07, 2025, Eledon Pharmaceuticals (ELDN) announced that tegoprubart, its investigational anti-CD40L antibody, was used as a key component of the immunosuppression therapy regimen in a patient who recently received . . . This content is …
Supernus Pharmaceuticals Supernus Pharmaceuticals (SUPN) - a biopharmaceutical company focused on developing products for the treatment of central nervous system (CNS) diseases, announced today that the U.S. Food and Drug Administration (FDA) approved ONAPGO (apomorphine hydrochloride) injection, formerly known as SPN-830, as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults . . . This content is for …
Halozyme Therapeutics Halozyme Therapeutics (HALO) announced that Janssen-Cilag International NV, a Johnson & Johnson company, received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommending an extension of marketing authorization for a subcutaneous (SC) formulation of RYBREVANT® (amivantamab) in combination with LAZCLUZE® (lazertinib) for . . . This content is for paid subscribers. Please click here …
Akero Therapeutics Full Press Release Following our shortened report earlier today, this posting is from the Company’s information and its press release. The news demonstrated statistically significant compensated cirrhosis (F4) reversal due to MASH by Both Completer and ITT Analyses at Week 96 in Phase 2b SYMMETRY Study. Akero Therapeutics (AKRO), released preliminary topline week 96 results from SYMMETRY . . . This content is …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
